Abstract

Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.

IPC Classes  ?

• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/426 - 1,3-Thiazoles
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 263/26 - Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
• C07D 277/14 - Oxygen atoms
• C07D 277/18 - Nitrogen atoms
• C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/107 - Emulsions
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.

IPC Classes  ?

• C07D 263/26 - Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
• C07D 277/14 - Oxygen atoms
• C07D 277/18 - Nitrogen atoms
• C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/426 - 1,3-Thiazoles
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Provided is the use of a CD24 protein for treating viral pneumonia.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61P 31/12 - Antivirals
• C12N 15/86 - Viral vectors

Abstract

Disclosed are a recombinant fusion protein derived from an HR region of an S2 protein of SARS-CoV-2 and an application of the recombinant fusion protein. The SARS-CoV-2 recombinant fusion protein is a recombinant fusion protein obtained by linking two membrane fusion-related conserved amino acid sequences HR1 and HR2 of the SARS-CoV-2 membrane protein S2 protein by means of a linking peptide. The recombinant fusion protein can be induced and expressed in Escherichia coli, has high expression quantity, and is easy to purify. The SARS-CoV-2 recombinant fusion protein provided by the present invention can form and maintain a stable dimer structure, simulates the conformation of a SARS-CoV-2 membrane fusion intermediate state, can be used as a detection raw material for detecting a SARS-CoV-2 membrane fusion process, has good anti-SARS-CoV-2 activity and good immunogenicity, and has a wide application prospect in the fields of development of drugs for preventing or treating SARS-CoV-2 proteins and development of SARS-CoV-2 vaccines and anti-SARS-CoV-2 antibodies.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present disclosure provides use of transferrin, a transferrin receptor and an antibody thereof in the preparation of an anti-SARS-CoV-2 drug. Use of the transferrin, the transferrin receptor or the transferrin receptor antibody in the preparation of an anti-SARS-CoV-2 drug is provided. Both surface plasmon resonance (SPR) and immunofluorescence confirm that the SARS-CoV-2 binds to the transferrin receptor through SARS-CoV-2 spike protein; the transferrin and/or the transferrin receptor antibody competitively bind(s) to the transferrin receptor of the body, or the transferrin receptor competitively binds to a site of the SARS-CoV-2 to inhibit binding of the SARS-CoV-2 to the transferrin receptor of the body; thus, the opportunity that the SARS-CoV-2 infects cells is blocked, and the antiviral effect of the body is realized. Use of the transferrin, the transferrin receptor and the antibody thereof in the preparation of a SARS-CoV-2 spike protein-binding biological product is provided

IPC Classes  ?

• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61P 31/14 - Antivirals for RNA viruses
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof

Abstract

Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/107 - Emulsions
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 31/14 - Antivirals for RNA viruses
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

An agent for inhibiting binding of transferrin receptor to SARS-CoV-2 spike protein or an anti-SARS-CoV-2 medicament is provided, where active pharmaceutical ingredients of the agent or the medicament include interference peptides, and the interference peptides include: SL8, FG8, DL12, RK4, SD6, HF7, and/or QK8.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/07 - Tetrapeptides
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 31/14 - Antivirals for RNA viruses
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The present disclosure provides use of a reagent for detecting an expression level of transferrin in the preparation of a diagnostic reagent or kit for a disease caused by imbalance of intestinal immune tolerance, and belongs to the technical field of medical molecular biology. In the present disclosure, the severity of intestinal inflammatory diseases is diagnosed according to the transferrin level, achieving the objective of the early diagnosis of the disease caused by imbalance of intestinal immune tolerance. In the present disclosure, the transferrin is used as a marker for imbalance of intestinal immune tolerance, featuring high specificity and sensitivity, and simple detection procedure.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

S. rhinocerous.

IPC Classes  ?

• A61D 19/02 - Instruments or methods for reproduction or fertilisation for artificial insemination
• A01K 61/10 - Culture of aquatic animals of fish
• A01K 61/17 - Hatching, e.g. incubators
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
• A61L 101/02 - Inorganic materials
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues

Abstract

S. grahami and carp to adapt to the artificial breeding environment quickly, realizes natural spermatogenesis and oviposition in artificial environment without using the oxytocin, and provides sperm and eggs both in quality and quantity for artificial hybridization. At the same time, the key parameters during incubation (including incubating water level, water temperature, water flow velocity, pH, dissolved oxygen and sterilization of fertilized eggs, etc.) are also defined to provide suitable environmental conditions for the successful incubation of fertilized eggs.

IPC Classes  ?

• A01K 61/17 - Hatching, e.g. incubators

Abstract

A use of Gemifibrozil and a pharmaceutically acceptable salt, ester, or stereoisomer thereof in the preparation of a medicament for the treatment and/or prevention of a neurodegenerative disease. The neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis. Further provided is a pharmaceutical composition for treating and/or preventing a neurodegenerative disease, wherein the pharmaceutical composition comprises Gemifibrozil, or a pharmaceutically acceptable salt, ester, or stereoisomer thereof, and, preferably, the pharmaceutical composition further comprises one or a plurality of pharmaceutically acceptable carriers. Further provided is a use of the pharmaceutical composition comprising Gemifibrozil, or a pharmaceutically acceptable salt, ester, or stereoisomer thereof in the preparation of a medicament for the treatment and/or prevention of a neurodegenerative disease.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Provided in the present invention is the use of transferrin, a transferrin receptor and an antibody thereof in the preparation of a drug for resisting SARS-CoV-2 virus, which belongs to the technical field of antiviral drugs. Provided is the use of transferrin, a transferrin receptor or a transferrin receptor antibody in the preparation of a drug for resisting SARS-CoV-2. Both surface plasmon resonance and immunofluorescence prove that SARS-CoV-2 binds to the transferrin receptor by means of a spike protein thereof, and the transferrin and/or the transferrin receptor antibody competitively bind/binds to the transferrin receptor of an organism, or the transferrin receptor competitively binds to a site of the SARS-CoV-2 to inhibit the binding of the SARS-CoV-2 to the transferrin receptor of the organism, thereby blocking the chance of infecting cells by the SARS-CoV-2 virus and achieving the antiviral effect of the organism. Further provided is the use of transferrin, a transferrin receptor and an antibody thereof in the preparation of a biological product combined with a spike protein of the SARS-CoV-2 virus.

IPC Classes  ?

• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Provided is a medicament for inhibiting the binding of a transferrin receptor and a SARS-CoV-2 spike protein, or an anti-SARS-CoV-2 drug, which is characterized in that active ingredients of the medicament or drug comprise an interference polypeptide, and the polypeptide comprises SL8, FG8, DL12, RK4, SD6, HF7 and/or QK8.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 38/07 - Tetrapeptides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Disclosed is use of Dalbavancin in the preparation of a medicament for inhibiting the binding of SARS-CoV-2 to ACE2, which belongs to the technical field of medicaments. Provided is pharmaceutical preparation use of Dalbavancin in resisting the activity of novel coronavirus by inhibiting the binding of SARS-CoV-2 to ACE2. Dalbavancin can be used in the preparation of a medicament for treating or preventing novel coronavirus pneumonia.

IPC Classes  ?

• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61P 31/14 - Antivirals for RNA viruses
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

A new application of an HUWE1 inhibitor BI8622 to inhibition of inflammasome activation. Researches discover that the HUWE1 inhibitor BI8622 can remarkably reduce activation of cysteine protease-1 (Caspase-1) and expression of interleukin 1β (IL-1β) in bone marrow derived macrophages (BMDM) of a mouse, and cell death is reduced; and meanwhile, it is proved that the BI8622 can remarkably reduce activation of the Caspase-1 and expression of the IL-1β in a human mononuclear macrophage line THP1 and human primary peripheral blood mononuclear cells (PBMC), and cell death is also remarkably reduced, so that the BI8622 can remarkably inhibit inflammasome activation.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Provided in the present invention are applications of a transferrin expression-detecting reagent in preparing a diagnostic reagent or reagent kit for intestinal immune tolerance disorders, related to the technical field of medical molecular biology. The present invention diagnoses the severity of onset of an intestinal inflammatory disease on the basis of the concentration level of transferrin and implements the goal of early diagnosis of intestinal immune tolerance disorders. The present invention has transferrin as an intestinal immune tolerance disorder marker, the specificity and sensitivity are high, and a detection method is simple.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided in the present invention are applications of transferrin or overexpressed transferrin in preparing a medicament for treating and/or preventing ulcerative colitis, related to the technical field of biomedicine. The present invention utilizes transferrin to inhibit intestinal inflammation and achieves the goal of treating ulcerative colitis. Transferrin provides an excellent effect for treating acute ulcerative colitis and chronic ulcerative colitis. The overexpression of transferrin inhibits colon tissue damage and colon shortening caused by acute ulcerative colitis and chronic ulcerative colitis, improves on the disease index caused by acute ulcerative colitis, and inhibits weight loss caused by acute ulcerative colitis.

IPC Classes  ?

• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to an application of nelfinavir in the preparation of a drug for preventing and treating novel coronavirus pneumonia. Specifically, the present invention relates to a use of nelfinavir and a pharmaceutical composition thereof as 2019 novel coronavirus (2019-nCov) 3CL proteinase inhibitors in the preparation of a drug for treating and/or preventing and alleviating related diseases caused by a 2019 novel coronavirus infection, such as a respiratory tract infection and pneumonia.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61P 31/14 - Antivirals for RNA viruses
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Provided is the use of a CD24 protein for treating viral pneumonia.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

Disclosed is a DACOs-type NNRTIs amino acid ester derivative, a preparation method thereof, a pharmaceutical composition, and an application thereof. The structure of the DACOs-type NNRTIs amino acid ester derivative is represented by formula (I). The DACOs-type NNRTIs amino acid ester derivative represented by formula (I) can be used as HIV-1 inhibitors and for the preparation of a drug for treating and/or preventing immunodeficiency viruses.

IPC Classes  ?

• C07D 239/56 - One oxygen atom and one sulfur atom
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

Disclosed is a pyrimidinone-containing compound represented by formula I, a preparation method thereof, a pharmaceutical composition, and an application thereof. The pyrimidinone-containing compound of the present disclosure can be used as HIV-1 inhibitor and can be also used in the treatment of human immunodeficiency virus infection.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

A use of Gemifibrozil and a pharmaceutically acceptable salt, ester, or stereoisomer thereof in the preparation of a medicament for the treatment and/or prevention of a neurodegenerative disease. The neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis. Further provided is a pharmaceutical composition for treating and/or preventing a neurodegenerative disease, wherein the pharmaceutical composition comprises the Gemifibrozil, or a pharmaceutically acceptable salt, ester, or stereoisomer thereof, and, preferably, the pharmaceutical composition further comprises one or a plurality of pharmaceutically acceptable carriers. Further provided is a use of the pharmaceutical composition comprising Gemifibrozil, or a pharmaceutically acceptable salt, ester, or stereoisomer thereof in the preparation of a medicament for the treatment and/or prevention of a neurodegenerative disease.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil

Abstract

The present invention relates to a method of treating, mitigating, minimizing, or preventing HIV-1/AIDS by administering a CD24 protein to a subject in need thereof. Also provided herein is use of a CD24 protein in the manufacture of a medicament for treating HIV-1/AIDS. Further, provided is a pharmaceutical composition comprising a pharmaceutically acceptable amount of a CD24 protein.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

31163623112366202106203a2103b441-6166 branched or linear alkoxy. The 2-thiomethylpyrazolopyrimidinone compound of the present invention can be used as an HIV-1 inhibitor and for the preparation of a drug for treating and/or preventing immunodeficiency viruses.

IPC Classes  ?

• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

116 36211236112211221121126202106202a2102b323266 heterocycloalkyl group. The DACOs-type NNRTIs amino acid ester derivatives of the present invention can be used as HIV-1 inhibitors and for the preparation of a drug for treating and/or preventing immunodeficiency viruses.

IPC Classes  ?

• C07D 239/56 - One oxygen atom and one sulfur atom
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The present invention provides use of 3,4,7-trihydroxyisoflavone or 3-methoxy daidzein in the preparation of medicaments for inhibiting platelet aggregation, the 3,4,7-trihydroxyisoflavone having a structure as represented by formula I, and the 3-methoxy daidzein having a structure as represented by formula II. The 3,4,7-trihydroxyisoflavone or 3-methoxy daidzein can significantly inhibit the platelet aggregation. In addition, examples of bleeding experiments indicate that none of the mice administered with the 3,4,7-trihydroxyisoflavone or 3-methoxy daidzein shows a significant bleeding activity, while the control group, a group administered with clopidogrel at the same concentration, shows a very significant bleeding activity. This indicates the use of the 3,4,7-trihydroxyisoflavone or 3-methoxy daidzein provided in the present invention in inhibiting platelet aggregation. The use of said medicaments can reduce the risk of bleeding, is safe, and allows for broader clinical and medical uses.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

Provided are a Haemadipsa sylvestris antithrombotic peptide sylvestin and the use thereof, falling within the technical field of biomedicine. The Haemadipsa sylvestris antithrombotic peptide sylvestin can inhibit FXIIa and kallikrein, has anti-thrombus/infarction effects and alleviates injuries caused by cerebral ischemia, and can also be used in the preparation of inhibitors of FXIIa and kallikrein and drugs for anti-thrombus/infarction and anti-cerebral ischemic injuries.

IPC Classes  ?

• C07K 14/815 - Protease inhibitors from leeches, e.g. hirudin, eglin
• C12N 15/15 - Protease inhibitors, e.g. antithrombin, antitrypsin, hirudin
• A61K 38/58 - Protease inhibitors from animalsProtease inhibitors from humans from leeches, e.g. hirudin, eglin
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Methods and kits useful for identifying a pig as producing an increased litter size are provided. Genetic makers, in particular SNP markers are provided that are useful in distinguishing pigs for a phenotype associated with increased litter size.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Disclosed are a skin analgesic peptide, FI, and a gene of same. Same comprises 6 amino acid residues, has a molecular weight of 717.87 Da and an isoelectric point of 5.52, and is of an amino acid sequence as represented by SEQ ID:1. The analgesic peptide, FI, is coded by a DNA sequence as represented by SEQ ID:2. Also disclosed are applications of the analgesic peptide in preparing an analgesic medicament.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C12N 15/12 - Genes encoding animal proteins
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed are applications of a small polypeptide, ZY31, in preparing an acne treatment, anti-infection, and anti-tumor medicament. The polypeptide comprises 15 amino acid residues, has a molecular weight of 2228.77 Da and an isoelectric point of 12.05, and is of an amino acid sequence as represented by SEQ ID:1. The polypeptide has a small molecular weight, is convenient to synthesize, provides a significant bacteriostatic effect, provides significant therapeutic effect for acne, also is capable of inhibiting tumor cell growth, and provides cytotoxicity against tumor cells.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 17/10 - Anti-acne agents
• A61P 35/00 - Antineoplastic agents

Abstract

A pharmaceutical composition for treating AIDS, preparation method therefor and use thereof. Raw medicines of the composition comprise: prepared aconite root, Herba Epimedii, Rhizoma Zingiberis, Radix Glycyrrhizae, Radix Ginseng, Radix Salviae Miltiorrhizae, Rhizoma Polygoni Cuspidati, Poria, Cortex Phellodendri, Radix Scutellaria and Euphorbiasteroid. It shows that the pharmaceutical composition has a substantial curative effect for treating the monkey AIDS virus infected rhesus-caused AIDS model, and can be applied to treat human AIDS. After persons infected with HIV or patients with AIDS take the pharmaceutical composition, the symptoms can be alleviated, CD4+T lymphocyte count of HIV infected persons and patients with AIDS is stabilized or raised, CD4+/CD8+ ratio level is improved, clinical signs are alleviated, and quality of life is improved.

IPC Classes  ?

• A61K 36/9068 - Zingiber, e.g. garden ginger
• A61K 36/756 - Phellodendron, e.g. corktree
• A61K 36/714 - Aconitum (monkshood)
• A61K 36/704 - Polygonum, e.g. knotweed
• A61K 36/539 - Scutellaria (skullcap)
• A61K 36/537 - Salvia (sage)
• A61K 36/47 - Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
• A61K 36/296 - Epimedium
• A61K 36/258 - Panax (ginseng)
• A61K 36/076 - Poria
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 31/18 - Sulfonamides

Abstract

Nitrogen-containing biphenyl compounds as represented by formula (I), pharmaceutically acceptable salts or derivatives thereof, pharmaceutical compositions, and preparation methods therefore, and anti-HIV-1 use of the compound. Each substituent group in formula (I) is as defined in the description.

IPC Classes  ?

• C07D 317/68 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

A horsefly protease tabfiblysin isolated from the salivary gland of the horsefly, Tabanus yao, a gene encoding the protease and use thereof are disclosed by the present invention. It belongs to the technical field of biomedicine. The molecular weight of the horsefly protease tabfiblysin is 27145.5 Daltons. Its full-length sequence is composed of 255 amino acids. Its encoding sequence is composed of 768 nucleotides. The horsefly protease tabfiblysin can hydrolyze fibrinogen and inhibit the aggregation of blood platelet dramatically, and can be used for preparing the drug for treating thrombotic diseases.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 15/57 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

The present invention relates to the application of 5-methyl-1,3-benzenediol or its derivatives represented by Formula I; wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them in the preparation of medicines or functional foods. The present studies indicate that 5-methyl-1,3-benzenediol or its derivatives represented by Formula I, wherein the constituent variables are as defined herein or pharmaceutical compositions thereof containing them show more significant antidepressant effects than fluoxetine or imipramine.

IPC Classes  ?

• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/05 - Phenols
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems

Abstract

The application of 3, 5-dihydroxytoluene or derivatives thereof or the composition comprising them in the preparation of medicine and functional food for treating or preventing depression. The research revealed that 3, 5-dihydroxytoluene or derivatives thereof had stronger antidepressed activity as compared with fluoxetine or imipramine.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61P 25/24 - Antidepressants
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;

Abstract

The use of 2,5-dihydroxyphenylmethanol or its derivates or its pharmaceutical composition in preparing the medicine or functional food for treating or preventing depression is provided in the present invention. The experiment results show that 2,5-dihydroxyphenylmethanol and its derivates and its pharmaceutical composition have the antidepressant activity, wherein the antidepressant activity of 2,6-dimethoxy benzoic acid-2,5-dihydroxy (2-glucosyl) benzene methyl ester is powerful over the activity of antidepressant fluoxetine.

IPC Classes  ?

• A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61P 25/24 - Antidepressants
• A23L 1/30 - containing additives (A23L 1/308 takes precedence);;

Abstract

This invention discloses the 2,4-disubstituted amido-6-substituted ⏧1,3,5] triazine or 1,3-pyrimidine derivatives of the general formula (I), in which the definitions of R1, R2, R3, R4, R5, R6, A, B, X, Y and Z are described as the description, their preparations, their pharmaceutical compositions and the pharmacological uses thereof. The compounds have high incorporation activity with HIV-1 integrase, and may effectively inhibit the incorporation of the integrase and the substrate in the substrate competition test. So, the compounds are relatively strong HIV-1 integrase inhibitors and are potential anti-HIV medicines.

IPC Classes  ?

• C07D 239/48 - Two nitrogen atoms
• C07D 239/50 - Three nitrogen atoms
• C07D 251/18 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
• C07D 251/54 - Three nitrogen atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/18 - Sulfonamides